Identification

Name
Ubidecarenone
Accession Number
DB09270
Type
Small Molecule
Groups
Approved, Investigational, Nutraceutical
Description

Ubidecarenone, also known as coenzyme Q10, is a 1,4-benzoquinone, where Q refers to the quinone chemical group, and 10 refers to the number of isoprenyl chemical subunits in its tail.[1] It is a powerful antioxidant, a lipid-soluble and essential cofactor in mitochondrial oxidative phosphorylation.[2] The ubidecarenone is the coenzyme destined for mitochondrial enzyme complexes involved in oxidative phosphorylation in the production of ATP. It is fundamental for cells that have a high metabolic demand.[7] Ubidecarenone is sold as a dietary supplement and is not FDA approved as a drug thus, it is not meant to treat, cure or prevent any disease. FDA does not approve this dietary supplements before sold nor regulate the manufacturing process.[8]

Structure
Thumb
Synonyms
  • Coenzyme Q-10
  • Coenzyme Q10
External IDs
API 31510 / API-31510 / NSC-140865
Product Ingredients
IngredientUNIICASInChI Key
Coenzyme q10, (2z)-U705VLF0VW65085-29-2ACTIUHUUMQJHFO-LLOLQPSSSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Co-enzyme Q-10 CapsulesCapsule30 mgOralAshbury Research CorporationNot applicableNot applicableCanada
Co-q10 (ubiquinone)Capsule60 mgOralAbundance Naturally LtdNot applicableNot applicableCanada
Q-gel Coenzyme Q10Capsule15 mgOralT & T Nutrition Inc.Not applicableNot applicableCanada
Watkins Coq10Tablet60 mgOralWatkins IncorporatedNot applicableNot applicableCanada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acti-ubiquinone 50 Cap 50mgCapsule50 mgOralActi Form Ltd.1991-12-312005-03-21Canada
Biogard Ubiquinone Cap 30mgCapsule30 mgOralSisu Inc.1994-12-312001-08-01Canada
Biomed Co Q 10Capsule100 mgOralSisu Inc.1998-02-112008-07-25Canada
Cell Tech Coenzyme Q10 - Cap 30mgCapsule30 mgOralCell Tech1996-11-122000-10-05Canada
Cellsparc 360Capsule60 mgOralAim International, Inc.1998-07-292008-09-03Canada
Co Q 10 - 50mg CapCapsule50 mgOralAlbi Naturals1994-12-312008-07-17Canada
Co-enzyme Q-10Capsule30 mgOralHolista Health (Canada) Inc.1996-12-312002-08-06Canada
Co-enzyme Q-10Capsule30 mgOralSeroyal International Inc.1995-12-312008-07-14Canada
Co-enzyme Q10 100mgCapsule100 mgOralNatural Factors Nutritional Products Ltd.1999-07-122009-09-28Canada
Co-enzyme Q10 30mg CapsulesCapsule30 mgOralAlive Vitamins1998-07-272005-07-04Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
BiosculptUbidecarenone (1.5 mg) + Choline bitartrate (0.3 mg) + Chromium (40 mcg) + Calcium pantothenate (60 mg) + Pyridoxine hydrochloride (4 mg) + myo-inositol (0.3 mg)SolutionOralMaxion Nutrition Corp.2002-06-102004-07-20Canada
Co-q10 and Vitamin EUbidecarenone (100 mg) + Vitamin E (300 unit)CapsuleOralBiomed International Products Corp.2003-10-012006-06-29Canada
Coenzyme Q10 +Ubidecarenone (30 mg) + Vitamin E (30 mg)CapsuleOralBody Wise International LlcNot applicableNot applicableCanada
Coenzyme Q10 Isotonix Vitamin and Mineral SupplementUbidecarenone (30.03 mg) + Potassium (32.43 mg) + Riboflavin (0.9 mg) + Vitamin E (60.06 mg)PowderOralMarket America2002-06-042008-09-04Canada
Daily Supplement PacksUbidecarenone (30 mg) + Cyanocobalamin (125 mcg) + Folic Acid (0.4 mg) + Magnesium (150 mg) + Pyridoxine (50 mg) + Vitamin E (400 unit)CapsuleOralWn Pharmaceuticals Ltd.2002-10-182005-08-15Canada
Formula BUbidecarenone (30 mg) + Magnesium (200 mg) + Pyridoxine (25 mg) + Thiamine (25 mg) + Vitamin C (250 mg) + Zinc (30 mg)CapsuleOralBalance Plus, Inc.2000-04-192004-08-17Canada
Formula DprUbidecarenone (30 mg) + Riboflavin (30 mg)CapsuleOralBalance Plus, Inc.2000-03-082004-08-17Canada
Formula Statin SupportUbidecarenone (30 mg) + Cyanocobalamin (50 mcg) + Magnesium (200 mg) + Pantothenic acid (50 mg) + Pyridoxine (50 mg)CapsuleOralBalance Plus, Inc.2000-04-192004-08-17Canada
L.I.P. ComplexUbidecarenone (10 mg) + Beta carotene (625 unit) + Cholecalciferol (200 unit) + Chromium (200 mcg) + Cyanocobalamin (50 mcg) + Folic Acid (0.4 mg) + Magnesium (50 mg) + Pyridoxine hydrochloride (50 mg) + Vitamin A palmitate (1875 unit) + Calcium ascorbate (100 mg) + Vitamin E (75 unit)TabletOralAbundance Marketing Ltd.2000-12-062004-06-30Canada
N.E.U. ComplexUbidecarenone (10 mg) + Cholecalciferol (400 unit) + Cyanocobalamin (50 mcg) + Folic Acid (0.4 mg) + Nicotinamide (25 mg) + Pyridoxine hydrochloride (10 mg) + Riboflavin (10 mg) + Thiamine Hydrochloride (10 mg) + Calcium ascorbate (150 mg) + Vitamin E (60 unit)TabletOralAbundance Marketing Ltd.2000-12-042004-06-30Canada
Categories
UNII
EJ27X76M46
CAS number
303-98-0
Weight
Average: 863.3435
Monoisotopic: 862.683911368
Chemical Formula
C59H90O4
InChI Key
ACTIUHUUMQJHFO-UPTCCGCDSA-N
InChI
InChI=1S/C59H90O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3/b45-26+,46-28+,47-30+,48-32+,49-34+,50-36+,51-38+,52-40+,53-42+
IUPAC Name
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
SMILES
COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O

Pharmacology

Indication

The diet supplements containing ubidecarenone are indicated, as stated in the product label, to assist individuals with cardiovascular complaints including congestive heart failure and systolic hypertension. In the product, ubidecarenone is used to increase the cardiac input as well as for the prevention of several other diseases like Parkinson, fibromyalgia, migraine, periodontal disease and diabetes, based on preclinical studies.[9] It is important to highlight that these products are not FDA approved and it is recommended to use under discretion.

Structured Indications
Not Available
Pharmacodynamics

Ubidecarenon has roles in many prysiological process including sulfide oxidation, regulation of mitochondrial permeability transition pore and translocation of protons and calcium ions accross biological membranes. Studies have shown its benefitial effect in treating cancer, statin myopathy, congestive heart failure and hypertension.[2]

Mechanism of action

Ubidecarenone is an essential cofactor in the mitochondrial electron transport chain. Its functions are the acceptance of electrons from the complex I and II and this activity is vital for the production of ATP. It acts as a mobile redox agent shuttling electrons and protons in the electron transport chain.[5] Ubidecarenone also presents antioxidant activity in mitochondria and cellular membranes, protecting against peroxidation of lipid membranes as well as inhibiting oxidation of LDL-cholesterol.[10]

TargetActionsOrganism
ANADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial
cofactor
Human
ASuccinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial
cofactor
Human
Absorption

Ubidecarenone is absorbed from the small intestine into the lymphatics and then it can enter the blood. The hydrophobicity and large molecular weight limit its absorption making it very poor and variable depending on the food intake and the number of lipids presented in the food. The absorption is lower in the presence of an empty stomach and greater in presence of high lipid food diet. The daily dosage of ubidecarenone presents the reach of maximal serum concentration by reaching a plateau after three weeks.[10] The pharmacokinetic properties may vary between different brands but studies have reported an AUC of 11.51 mcg h/ml and a Cmax of 0.32 mcg/ml at a time of 7.9 h.[3]

Volume of distribution

Ubidecarenone is distributed to the various tissues of the body and it is able to enter the brain.[10] In preclinical studies with intravenous administration of ubidecarenone, it is reported a volume of distribution of 20.4 L/kg which reflects its ability to penetrate extensively into organs and tissues.[4] AS a general rule, tissues with high-energy requirements or metabolic activity tend to presents higher amounts of ubidecarenone, these organs can be heart, kidney, liver and muscle.[5]

Protein binding

In the blood, ubidecarenone is split into the various lipoprotein particles including LDL and VLDL.[10] The plasma concentration of ubidecarenone is highly dependent on the presence of plasma lipoproteins and about 95% of the administered form is found in the reduced form.[5]

Metabolism

Studies indicate that there is no saturation process during the metabolism of ubidecarenone. It is metabolized in all tissues by the phosphorylation in the cells and transportation to the kidneys for further excretion by the urine.[11] After exerting its action, ubidecarenone is reduced and forms hydroquinone which is capable of recycling and regenerates other antioxidants such as tocopherol and ascorbate. The later metabolism of hydroquinone generates the formation of Q acid I and Q acid II in free and conjugated forms.[5]

Route of elimination

The main elimination route of ubidecarenone is through the bile. After its oral administration, over 60% of the dose is excreted in the feces in the form of unchanged ubidecarenone and a small fraction of the metabolites.[10, 5] In the urine, ubidecarenone is bound to saposin B protein and represents only 8.3% of the total administered dose.[5]

Half life

The pharmacokinetic properties may vary between different brands but studies have reported a half-life of ubidecarenone of 21.7 h.[3]

Clearance

In preclinical studies with intravenous administration of ubidecarenone, it is reported a total clearance of 1.18 ml h/kg which was indicative of a prolonged elimination.[4]

Toxicity

There have not been reports of adverse events of diet supplementation with ubidecarenone.[6] The normal side effects reported in humans are related to the gastrointestinal tract.[5]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Ubidecarenone.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Ubidecarenone.Approved, Investigational
AcenocoumarolUbidecarenone may decrease the anticoagulant activities of Acenocoumarol.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be increased when used in combination with Ubidecarenone.Investigational, Withdrawn
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Ubidecarenone.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be increased when used in combination with Ubidecarenone.Experimental, Investigational
AllicinThe therapeutic efficacy of Allicin can be increased when used in combination with Ubidecarenone.Investigational
AlmasilateThe serum concentration of Ubidecarenone can be decreased when it is combined with Almasilate.Approved, Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be increased when used in combination with Ubidecarenone.Approved
AloglutamolThe serum concentration of Ubidecarenone can be decreased when it is combined with Aloglutamol.Experimental
AluminiumThe serum concentration of Ubidecarenone can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Ubidecarenone can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Ubidecarenone can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Ubidecarenone can be decreased when it is combined with Aluminum hydroxide.Approved
AmiodaroneThe metabolism of Ubidecarenone can be decreased when combined with Amiodarone.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Amrinone is combined with Ubidecarenone.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Ubidecarenone.Approved, Investigational
AzimilideThe risk or severity of adverse effects can be increased when Azimilide is combined with Ubidecarenone.Investigational
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be increased when used in combination with Ubidecarenone.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Ubidecarenone.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be increased when used in combination with Ubidecarenone.Investigational
BencyclaneThe risk or severity of adverse effects can be increased when Bencyclane is combined with Ubidecarenone.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Benidipine is combined with Ubidecarenone.Approved, Investigational
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Ubidecarenone.Approved, Withdrawn
BezafibrateBezafibrate may increase the myopathic rhabdomyolysis activities of Ubidecarenone.Approved
Bismuth SubcitrateThe serum concentration of Ubidecarenone can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Ubidecarenone can be decreased when it is combined with Bismuth subnitrate.Experimental
BosentanThe metabolism of Ubidecarenone can be increased when combined with Bosentan.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be increased when used in combination with Ubidecarenone.Investigational, Withdrawn
Calcium CarbonateThe serum concentration of Ubidecarenone can be decreased when it is combined with Calcium Carbonate.Approved
Calcium silicateThe serum concentration of Ubidecarenone can be decreased when it is combined with Calcium silicate.Experimental
CanagliflozinThe therapeutic efficacy of Canagliflozin can be increased when used in combination with Ubidecarenone.Approved
CarbomycinThe risk or severity of adverse effects can be increased when Carbomycin is combined with Ubidecarenone.Vet Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Ubidecarenone.Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be increased when used in combination with Ubidecarenone.Experimental
CaroverineThe risk or severity of adverse effects can be increased when Caroverine is combined with Ubidecarenone.Experimental
CastanospermineThe therapeutic efficacy of Castanospermine can be increased when used in combination with Ubidecarenone.Experimental
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be increased when used in combination with Ubidecarenone.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be increased when used in combination with Ubidecarenone.Experimental
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Ubidecarenone.Approved, Investigational
CinnarizineThe risk or severity of adverse effects can be increased when Cinnarizine is combined with Ubidecarenone.Approved, Investigational
CiprofibrateThe risk or severity of adverse effects can be increased when Ciprofibrate is combined with Ubidecarenone.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Ubidecarenone.Approved
ClorindioneUbidecarenone may decrease the anticoagulant activities of Clorindione.Experimental
ColchicineColchicine may increase the myopathic rhabdomyolysis activities of Ubidecarenone.Approved
Cyproterone acetateThe serum concentration of Ubidecarenone can be increased when it is combined with Cyproterone acetate.Approved, Investigational
DaclatasvirThe serum concentration of Ubidecarenone can be increased when it is combined with Daclatasvir.Approved
DaptomycinThe risk or severity of adverse effects can be increased when Ubidecarenone is combined with Daptomycin.Approved, Investigational
DarodipineThe risk or severity of adverse effects can be increased when Darodipine is combined with Ubidecarenone.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be increased when used in combination with Ubidecarenone.Investigational
DicoumarolUbidecarenone may decrease the anticoagulant activities of Dicoumarol.Approved
DiphenadioneUbidecarenone may decrease the anticoagulant activities of Diphenadione.Experimental
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Ubidecarenone.Investigational
DoxorubicinThe risk or severity of adverse effects can be decreased when Ubidecarenone is combined with Doxorubicin.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be increased when used in combination with Ubidecarenone.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Ubidecarenone.Approved, Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be increased when used in combination with Ubidecarenone.Approved
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Ubidecarenone.Approved, Investigational
ErlotinibThe risk or severity of adverse effects can be increased when Erlotinib is combined with Ubidecarenone.Approved, Investigational
Ethyl biscoumacetateUbidecarenone may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtravirineThe serum concentration of Ubidecarenone can be decreased when it is combined with Etravirine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be increased when used in combination with Ubidecarenone.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Fendiline is combined with Ubidecarenone.Withdrawn
FidaxomicinThe risk or severity of adverse effects can be increased when Fidaxomicin is combined with Ubidecarenone.Approved
FluindioneUbidecarenone may decrease the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ubidecarenone.Approved
FosphenytoinThe serum concentration of Ubidecarenone can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe risk or severity of adverse effects can be increased when Fusidic Acid is combined with Ubidecarenone.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ubidecarenone.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Gallopamil is combined with Ubidecarenone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be increased when used in combination with Ubidecarenone.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be increased when used in combination with Ubidecarenone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be increased when used in combination with Ubidecarenone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be increased when used in combination with Ubidecarenone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be increased when used in combination with Ubidecarenone.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be increased when used in combination with Ubidecarenone.Approved
GusperimusThe therapeutic efficacy of Gusperimus can be increased when used in combination with Ubidecarenone.Investigational
HydrotalciteThe serum concentration of Ubidecarenone can be decreased when it is combined with Hydrotalcite.Experimental, Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be increased when used in combination with Ubidecarenone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be increased when used in combination with Ubidecarenone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be increased when used in combination with Ubidecarenone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be increased when used in combination with Ubidecarenone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be increased when used in combination with Ubidecarenone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be increased when used in combination with Ubidecarenone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be increased when used in combination with Ubidecarenone.Approved
KitasamycinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Ubidecarenone.Experimental
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Ubidecarenone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ubidecarenone.Approved, Investigational
Lanthanum carbonateThe serum concentration of Lanthanum carbonate can be decreased when it is combined with Ubidecarenone.Approved
LidoflazineThe risk or severity of adverse effects can be increased when Lidoflazine is combined with Ubidecarenone.Experimental
LinagliptinThe therapeutic efficacy of Linagliptin can be increased when used in combination with Ubidecarenone.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be increased when used in combination with Ubidecarenone.Approved
LumacaftorThe serum concentration of Ubidecarenone can be decreased when it is combined with Lumacaftor.Approved
MagaldrateThe serum concentration of Ubidecarenone can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Ubidecarenone.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium Trisilicate.Approved
MetforminThe therapeutic efficacy of Metformin can be increased when used in combination with Ubidecarenone.Approved
MiglitolThe therapeutic efficacy of Miglitol can be increased when used in combination with Ubidecarenone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be increased when used in combination with Ubidecarenone.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be increased when used in combination with Ubidecarenone.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Ubidecarenone.Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be increased when used in combination with Ubidecarenone.Approved, Investigational
NiacinThe risk or severity of adverse effects can be increased when Niacin is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
NiguldipineThe risk or severity of adverse effects can be increased when Niguldipine is combined with Ubidecarenone.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Niludipine is combined with Ubidecarenone.Experimental
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ubidecarenone.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Ubidecarenone.Approved
OleandomycinThe risk or severity of adverse effects can be increased when Oleandomycin is combined with Ubidecarenone.Vet Approved
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Ubidecarenone.Experimental, Investigational
PazopanibUbidecarenone may increase the hepatotoxic activities of Pazopanib.Approved
PerhexilineThe risk or severity of adverse effects can be increased when Perhexiline is combined with Ubidecarenone.Approved, Investigational
PhenforminThe therapeutic efficacy of Phenformin can be increased when used in combination with Ubidecarenone.Approved, Investigational, Withdrawn
PhenindioneUbidecarenone may decrease the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonUbidecarenone may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe serum concentration of Ubidecarenone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PinaveriumThe risk or severity of adverse effects can be increased when Pinaverium is combined with Ubidecarenone.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be increased when used in combination with Ubidecarenone.Approved, Investigational
PiperineThe serum concentration of Ubidecarenone can be increased when it is combined with Piperine.Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be increased when used in combination with Ubidecarenone.Approved, Investigational
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ubidecarenone.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Prenylamine is combined with Ubidecarenone.Withdrawn
PropranololThe therapeutic efficacy of Ubidecarenone can be decreased when used in combination with Propranolol.Approved, Investigational
QuinineThe serum concentration of Ubidecarenone can be increased when it is combined with Quinine.Approved
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Ubidecarenone.Approved
RanolazineThe serum concentration of Ubidecarenone can be increased when it is combined with Ranolazine.Approved, Investigational
RepaglinideThe therapeutic efficacy of Repaglinide can be increased when used in combination with Ubidecarenone.Approved, Investigational
RifabutinThe serum concentration of Ubidecarenone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Ubidecarenone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Ubidecarenone can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Ubidecarenone can be decreased when it is combined with Rifaximin.Approved, Investigational
RisedronateThe risk or severity of adverse effects can be increased when Risedronate is combined with Ubidecarenone.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be increased when used in combination with Ubidecarenone.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be increased when used in combination with Ubidecarenone.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be increased when used in combination with Ubidecarenone.Approved, Investigational
Sodium bicarbonateThe serum concentration of Ubidecarenone can be decreased when it is combined with Sodium bicarbonate.Approved
SolithromycinThe risk or severity of adverse effects can be increased when Solithromycin is combined with Ubidecarenone.Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be increased when used in combination with Ubidecarenone.Investigational
SpiramycinThe risk or severity of adverse effects can be increased when Spiramycin is combined with Ubidecarenone.Approved
St. John's WortThe metabolism of Ubidecarenone can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
SulodexideThe therapeutic efficacy of Sulodexide can be increased when used in combination with Ubidecarenone.Approved, Investigational
TerodilineThe risk or severity of adverse effects can be increased when Terodiline is combined with Ubidecarenone.Experimental
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ubidecarenone.Investigational
TioclomarolUbidecarenone may decrease the anticoagulant activities of Tioclomarol.Experimental
TolazamideThe therapeutic efficacy of Tolazamide can be increased when used in combination with Ubidecarenone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be increased when used in combination with Ubidecarenone.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ubidecarenone.Approved
TrabectedinUbidecarenone may increase the myopathic rhabdomyolysis activities of Trabectedin.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Ubidecarenone.Approved, Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be increased when used in combination with Ubidecarenone.Investigational, Withdrawn
TromethamineThe serum concentration of Ubidecarenone can be decreased when it is combined with Tromethamine.Approved
TylosinThe risk or severity of adverse effects can be increased when Tylosin is combined with Ubidecarenone.Vet Approved
VemurafenibThe serum concentration of Ubidecarenone can be increased when it is combined with Vemurafenib.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be increased when used in combination with Ubidecarenone.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Ubidecarenone.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be increased when used in combination with Ubidecarenone.Approved, Investigational
WarfarinThe therapeutic efficacy of Warfarin can be decreased when used in combination with Ubidecarenone.Approved
XylometazolineThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Ubidecarenone.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ubidecarenone.Approved
Food Interactions
Not Available

References

General References
  1. Ernster L, Dallner G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995 May 24;1271(1):195-204. [PubMed:7599208]
  2. Xue R, Yang J, Wu J, Meng Q, Hao J: Coenzyme Q10 inhibits the activation of pancreatic stellate cells through PI3K/AKT/mTOR signaling pathway. Oncotarget. 2017 Sep 23;8(54):92300-92311. doi: 10.18632/oncotarget.21247. eCollection 2017 Nov 3. [PubMed:29190916]
  3. Kang EY, Choi JW, Gwak HS, Chun IK: Comparison of bioavailability of two ubidecarenone products in healthy Korean volunteers. Int J Clin Pharmacol Ther. 2009 Mar;47(3):207-14. [PubMed:19281730]
  4. Kalenikova EI, Gorodetskaya EA, Medvedev OS: Pharmacokinetics of coenzyme q10. Bull Exp Biol Med. 2008 Sep;146(3):313-6. [PubMed:19240848]
  5. Bhagavan HN, Chopra RK: Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006 May;40(5):445-53. doi: 10.1080/10715760600617843. [PubMed:16551570]
  6. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M: Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct;59(10):1541-50. [PubMed:12374491]
  7. FDA Reports [Link]
  8. Pubmedhealth [Link]
  9. Diet supplement label [Link]
  10. Coenzyme Q [Link]
  11. Journal of Health Science [Link]
External Links
Human Metabolome Database
HMDB0001072
KEGG Drug
D01065
KEGG Compound
C11378
PubChem Compound
5281915
PubChem Substance
310265165
ChemSpider
4445197
ChEBI
46245
ChEMBL
CHEMBL454801
HET
U10
Wikipedia
Coenzyme_Q10
ATC Codes
C01EB09 — Ubidecarenone
AHFS Codes
  • 88:30.00* — Other Nutritional Agents
PDB Entries
1aig / 1aij / 1bcc / 1ds8 / 1dv3 / 1dv6 / 1e14 / 1e6d / 1f6n / 1fnp
show 93 more
MSDS
Download (92.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingSupportive CareCancer, Breast1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedSupportive CareSporadic Ataxia1
1, 2CompletedSupportive CareCharcot Marie Tooth Disease1
1, 2CompletedTreatmentSquamous Cell Carcinoma (SCC)1
1, 2Not Yet RecruitingSupportive CareQuality of Life1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS) / Lou Gehrig's Disease1
2CompletedTreatmentCardiac Arrest / Sudden Cardiac Arrest1
2CompletedTreatmentHuntington's Disease (HD)1
2CompletedTreatmentMuscular Dystrophy, Duchenne1
2CompletedTreatmentNon-Proliferative Diabetic Retinopathy / Type 2 Diabetes Mellitus1
2CompletedTreatmentParkinson's Disease (PD)2
2CompletedTreatmentProgressive Supranuclear Palsy (PSP)1
2CompletedTreatmentSuperficial Basal Cell Carcinoma1
2Not Yet RecruitingTreatmentHeart Failure, Diastolic1
2Not Yet RecruitingTreatmentHeart Failure, Unspecified1
2RecruitingTreatmentMalignant Neoplasm of Pancreas1
2WithdrawnNot AvailableBipolar Affective Disorders / Depression1
2WithdrawnTreatmentSquamous Cell Carcinoma (SCC)1
2, 3CompletedTreatmentAtypical Parkinsonism / Progressive Supranuclear Palsy (PSP)1
2, 3CompletedTreatmentNeurological Disorders / Progressive Supranuclear Palsy (PSP)1
2, 3Enrolling by InvitationTreatmentBecker's Muscular Dystrophy (BMD) / Duchenne's Muscular Dystrophy (DMD) / Limb Girdle Muscular Dystrophy1
3TerminatedTreatmentHuntington's Disease (HD)1
4CompletedTreatmentChronic Renal Failure (CRF) / Hemodialysis-dependent patients1
4CompletedTreatmentCongestive Cardiomyopathy1
4CompletedTreatmentMuscle Soreness / Muscle Weakness / Side Effects of Statins1
4RecruitingTreatmentIdiopathic Infertility1
Not AvailableCompletedBasic ScienceDepression, Bipolar2
Not AvailableCompletedTreatmentPolycystic Ovaries Syndrome1
Not AvailableNot Yet RecruitingTreatmentOral Aphthous Ulcer1
Not AvailableUnknown StatusBasic ScienceStatin Myopathy1
Not AvailableUnknown StatusTreatmentCoenzyme Q10 on Athero-thrombosis in APS Patients1
Not AvailableUnknown StatusTreatmentCongestive Heart Failure (CHF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral50 mg
CapsuleOral100 mg
SolutionOral
TabletOral10 mg
CapsuleOral50.0 mg
CapsuleOral12 mg
TabletOral100 mg
CapsuleOral60 mg
CapsuleOral80 mg
CapsuleOral15 mg
CapsuleOral30 mg
PowderOral
CapsuleOral10 mg
TabletOral
CapsuleOral
TabletOral60 mg
CapsuleOral25 mg
CapsuleOral20 mg
Capsule, gelatin coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)50-52ºCMSDS
water solubilitySparingly solubleMSDS
logP10Lucangioli S. and Tripodi V., Der Pharmacia Sinica, (2012), 3 (4):406-407
Predicted Properties
PropertyValueSource
Water Solubility0.000193 mg/mLALOGPS
logP9.94ALOGPS
logP17.16ChemAxon
logS-6.6ALOGPS
pKa (Strongest Basic)-4.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area52.6 Å2ChemAxon
Rotatable Bond Count31ChemAxon
Refractivity286.61 m3·mol-1ChemAxon
Polarizability112.38 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03dj-0211112090-13e67655f61e48a95d91
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00kb-0859598220-67d1d2437197bf4977c9
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-014j-1132229710-87eed3c798b1c43399ec
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-03di-0000000090-68b5c91d1736a6033778
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-08fs-0100000390-3f2c6d6cc684a14c6586
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-000b-8100000890-af49da707a25798624ae

Taxonomy

Description
This compound belongs to the class of organic compounds known as ubiquinones. These are coenzyme Q derivatives containing a 5, 6-dimethoxy-3-methyl(1,4-benzoquinone) moiety to which an isoprenyl group is attached at ring position 2(or 6).
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Quinone and hydroquinone lipids
Direct Parent
Ubiquinones
Alternative Parents
Polyterpenoids / Polyprenylbenzoquinones / P-benzoquinones / Vinylogous esters / Organic oxides / Hydrocarbon derivatives
Substituents
Polyterpenoid / Polyprenylbenzoquinone / Ubiquinone skeleton / Quinone / P-benzoquinone / Vinylogous ester / Cyclic ketone / Ketone / Organic oxygen compound / Organic oxide
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
ubiquinones (CHEBI:46245) / ubiquinones, Coenzymes (C11378) / Ubiquinones (LMPR02010001)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Cofactor
General Function
Poly(a) rna binding
Specific Function
Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons ...
Gene Name
NDUFV3
Uniprot ID
P56181
Uniprot Name
NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial
Molecular Weight
11940.435 Da
References
  1. Bhagavan HN, Chopra RK: Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006 May;40(5):445-53. doi: 10.1080/10715760600617843. [PubMed:16551570]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Cofactor
General Function
Succinate dehydrogenase activity
Specific Function
Flavoprotein (FP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate ...
Gene Name
SDHA
Uniprot ID
P31040
Uniprot Name
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial
Molecular Weight
72690.975 Da
References
  1. Bhagavan HN, Chopra RK: Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006 May;40(5):445-53. doi: 10.1080/10715760600617843. [PubMed:16551570]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Nadph binding
Specific Function
Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including...
Gene Name
HMGCR
Uniprot ID
P04035
Uniprot Name
3-hydroxy-3-methylglutaryl-coenzyme A reductase
Molecular Weight
97475.155 Da
References
  1. Coenzyme Q [Link]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Virus receptor activity
Specific Function
Binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clat...
Gene Name
LDLR
Uniprot ID
P01130
Uniprot Name
Low-density lipoprotein receptor
Molecular Weight
95375.105 Da
References
  1. Coenzyme Q [Link]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Very-low-density lipoprotein particle receptor activity
Specific Function
Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine p...
Gene Name
VLDLR
Uniprot ID
P98155
Uniprot Name
Very low-density lipoprotein receptor
Molecular Weight
96097.45 Da
References
  1. Coenzyme Q [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Journal of Health Science [Link]

Drug created on October 28, 2015 09:41 / Updated on January 23, 2018 12:21